PDF
(Download)
|
- Aloe (Aloe vera syn. A. barbadensis)
- Human Immunodeficiency Virus (HIV)
|
Date:
01-31-2013 | HC# 101212-465
|
Re: Preliminary Clinical Trial Indicates Aloe May Be Beneficial for Patients with HIV
Olatunya OS,
Olatunya AM, Anyabolu HC, Adejuyigbe EA, Oyelami OA. Preliminary trial of aloe
vera gruel on HIV Infection. J Altern
Complement Med. September 2012;18(9):850-853.
Human
immunodeficiency virus (HIV) is an RNA retrovirus that belongs to the
lentivirus family and is associated with a chronic course of disease. Both HIV
types 1 and 2 have been documented as causative agents of acquired
immunodeficiency syndrome (AIDS), which is the end stage of the disease state
caused by HIV infections. HIV has become a world pandemic, and about 80% of
those infected live in sub-Saharan Africa. HIV attacks the lymphocyte sub-group
(T helper cells) that express the CD4 surface protein, or in short, CD4 cells. Nigerian
guidelines suggest a CD4 count of ≤200 cells/µL as the eligibility criteria for
the use of highly active antiretroviral treatment (HAART), but due to poor drug
access, only 17% of these eligible participants actually receive HAART.
Aloe
(Aloe vera syn. A. barbadensis) is a succulent indigenous to sub-Saharan Africa
that has shown antiviral properties against HIV in vitro. The stiff outer portion
of the leaf or rind contains laxative anthraquinones, while the inner pulp or
gel is a rich source of polysaccharides, minerals, trace elements, vitamins, and
amino acids. Aloe gel has shown glutathione peroxidase and superoxide dismutase
activity in vitro, as well as immune modulatory activity. It is generally
considered safe for consumption and only minor adverse side effects were reported
in a 2004 clinical trial.1 This 12-month pilot study evaluated
changes in weight and CD4 counts in HIV patients consuming aloe compared to
age-controlled cases receiving HAART.
A
total of 10 HIV-infected mothers between the ages of 25 and 40 years were
recruited for the aloe case study from Wesley Guild Hospital Ilesa, a unit of
Obafemi Awolowo University Teaching Hospital in Ile Ife, Nigeria. These women
did not meet the Nigerian criteria for HAART, with the exception of 1 patient
who was initially on HAART but stopped because of unbearable adverse effects.
"They
were given 30-40 mL of blended aloe gruel daily." The aloe vera tongues
were harvested from a local plantation and the identity of these plants was confirmed
at the Faculty of Pharmacy Herbarium, Obafemi Awolowo University, Ile Ife,
Nigeria. Neither the leaf part(s) used, the gruel preparation method, nor the gruel
concentration was described.
The
CD4 counts, weight, liver function, electrolytes, urea, creatinine, hemogram
(full blood count), and the physical wellbeing of all patients were monitored
over the course of the study from October 2008 to October 2009. CD4 counts and
weight at baseline, 6, and 12 months were compared to 20 age-matched controls
(HIV-positive mothers) that were managed with HAART.
The
average increase in CD4 count was 154 cells/µL (range: 94-300 cells/µL) in the
aloe cases, while the increase in the HAART group was 239 cells/µL (range: 68-642
cells/µL). In the aloe cases, the average weight gain was 4.7 kg (range: 3-7
kg) compared to 4.8 kg (range: 1-7 kg) in the HAART cases. Using the
independent samples T-test to analyze the CD4 and weight data, there was no
statistically significant difference between the 2 groups (P=0.087 and P=0.916,
respectively).
The
authors of this preliminary study point out that although case-controlled
studies do not provide the highest level of evidence, ethical considerations
precluded both the inclusion of a placebo group and denial of treatment to
patients eligible for HAART. They also note that the positive HAART case controls
used in this study were not ideal because these patients had much lower CD4
counts at baseline and were less physically fit than the aloe cases. Nonetheless,
the patients consuming aloe had CD4 count increases and weight gains similar to
the HAART group, with fewer adverse effects. Despite the limitations of this
study, the authors suggest that aloe may be an inexpensive and readily
available treatment alternative for patients not eligible for or not able to
access HAART.
—Laura
M. Bystrom, PhD
Editorial
Comment:
In
addition to the ambiguous description of the aloe gruel, the case controls and
statistical analyses may also be questioned. Case-controlled studies are typically
1:1 comparisons of active cases to matched cases; the 1:2 comparison of aloe to
HAART cases in this study may have skewed the data. The cases were only matched
for age, a variable which may have less significance than the weight endpoint. A
1:1 comparison of weight-matched cases may have provided a more rigorous
assessment of the 2 therapies.
Reference
1Oliff HS. Clinical trial on aloe gel for the treatment
of acute ulcerative colitis. HerbClip.
July 15, 2005 (No. 020451-284). Austin, TX: American Botanical Council. Review
of Randomized, double-blind, placebo-controlled trial of oral aloe vera gel
for active ulcerative colitis by Langmead L, Feakins RM, Goldthorpe S, et al. Aliment Pharmacol Ther. April 1,
2004;19(7):739-747.
|